181 related articles for article (PubMed ID: 15034050)
41. Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System.
Laursen NS; Pedersen DV; Gytz H; Zarantonello A; Bernth Jensen JM; Hansen AG; Thiel S; Andersen GR
Front Immunol; 2020; 11():1504. PubMed ID: 32849513
[TBL] [Abstract][Full Text] [Related]
42. Lupus nephritis sera contain autoantibodies that recognize epitopes within the globular fragment of C1q.
Deliyska B; Tsacheva I; Radanova M; Stoianova V; Tchorbadjieva M; Dobreva N
Med Pregl; 2007; 60 Suppl 2():25-7. PubMed ID: 18928152
[TBL] [Abstract][Full Text] [Related]
43. Trimeric reassembly of the globular domain of human C1q.
Tacnet P; Cheong EC; Goeltz P; Ghebrehiwet B; Arlaud GJ; Liu XY; Lesieur C
Biochim Biophys Acta; 2008 Mar; 1784(3):518-29. PubMed ID: 18179779
[TBL] [Abstract][Full Text] [Related]
44. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
45. AiC1qDC-1, a novel gC1q-domain-containing protein from bay scallop Argopecten irradians with fungi agglutinating activity.
Kong P; Zhang H; Wang L; Zhou Z; Yang J; Zhang Y; Qiu L; Wang L; Song L
Dev Comp Immunol; 2010 Aug; 34(8):837-46. PubMed ID: 20346969
[TBL] [Abstract][Full Text] [Related]
46. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
[TBL] [Abstract][Full Text] [Related]
47. A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses.
Chen CH; Boackle RJ
Clin Immunol Immunopathol; 1998 Apr; 87(1):68-74. PubMed ID: 9576012
[TBL] [Abstract][Full Text] [Related]
48. The receptor for the globular "heads" of C1q, gC1q-R, binds to fibrinogen/fibrin and impairs its polymerization.
Lu PD; Galanakis DK; Ghebrehiwet B; Peerschke EI
Clin Immunol; 1999 Mar; 90(3):360-7. PubMed ID: 10075865
[TBL] [Abstract][Full Text] [Related]
49. Analysis of binding sites in human C-reactive protein for Fc{gamma}RI, Fc{gamma}RIIA, and C1q by site-directed mutagenesis.
Bang R; Marnell L; Mold C; Stein MP; Clos KT; Chivington-Buck C; Clos TW
J Biol Chem; 2005 Jul; 280(26):25095-102. PubMed ID: 15878871
[TBL] [Abstract][Full Text] [Related]
50. Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes.
Gorgani NN; Parish CR; Easterbrook Smith SB; Altin JG
Biochemistry; 1997 Jun; 36(22):6653-62. PubMed ID: 9184145
[TBL] [Abstract][Full Text] [Related]
51. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties.
Gaboriaud C; Juanhuix J; Gruez A; Lacroix M; Darnault C; Pignol D; Verger D; Fontecilla-Camps JC; Arlaud GJ
J Biol Chem; 2003 Nov; 278(47):46974-82. PubMed ID: 12960167
[TBL] [Abstract][Full Text] [Related]
52. Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.
Hwang HY; Duvall MR; Tomlinson S; Boackle RJ
Mol Immunol; 2008 May; 45(9):2570-80. PubMed ID: 18313756
[TBL] [Abstract][Full Text] [Related]
53. Heme interacts with c1q and inhibits the classical complement pathway.
Roumenina LT; Radanova M; Atanasov BP; Popov KT; Kaveri SV; Lacroix-Desmazes S; Frémeaux-Bacchi V; Dimitrov JD
J Biol Chem; 2011 May; 286(18):16459-69. PubMed ID: 21454703
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of C1-mediated immune hemolysis by monomeric and dimeric peptides from the second constant domain of human immunoglobulin G.
Lukas TJ; Muñoz H; Erickson BW
J Immunol; 1981 Dec; 127(6):2555-60. PubMed ID: 7299136
[TBL] [Abstract][Full Text] [Related]
55. Staphylococcal superantigen-like protein 10 (SSL10) binds to human immunoglobulin G (IgG) and inhibits complement activation via the classical pathway.
Itoh S; Hamada E; Kamoshida G; Yokoyama R; Takii T; Onozaki K; Tsuji T
Mol Immunol; 2010 Jan; 47(4):932-8. PubMed ID: 19913916
[TBL] [Abstract][Full Text] [Related]
56. Inhibition by various peptides of the activation of C1, the first component of complement, and the interaction of C gamma 2 domain of IgG with C1q.
Takada A; Shirahama S; Takada Y
Immunopharmacology; 1985 Apr; 9(2):87-95. PubMed ID: 3888918
[TBL] [Abstract][Full Text] [Related]
57. Mass spectrometry analysis of the oligomeric C1q protein reveals the B chain as the target of trypsin cleavage and interaction with fucoidan.
Tissot B; Gonnet F; Iborra A; Berthou C; Thielens N; Arlaud GJ; Daniel R
Biochemistry; 2005 Feb; 44(7):2602-9. PubMed ID: 15709773
[TBL] [Abstract][Full Text] [Related]
58. Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain.
Jiang H; Robey FA; Gewurz H
J Exp Med; 1992 May; 175(5):1373-9. PubMed ID: 1569403
[TBL] [Abstract][Full Text] [Related]
59. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region.
McGrath FD; Brouwer MC; Arlaud GJ; Daha MR; Hack CE; Roos A
J Immunol; 2006 Mar; 176(5):2950-7. PubMed ID: 16493053
[TBL] [Abstract][Full Text] [Related]
60. Identification of functional domains on gC1Q-R, a cell surface protein that binds to the globular "heads" of C1Q, using monoclonal antibodies and synthetic peptides.
Ghebrehiwet B; Lu PD; Zhang W; Lim BL; Eggleton P; Leigh LE; Reid KB; Peerschke EI
Hybridoma; 1996 Oct; 15(5):333-42. PubMed ID: 8913782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
